Evidence map›Paper›PMID 40464804›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Head-to-head comparison of

Wenhui Ma, Shu Yang, Jiajun Ye, Zhiyong Quan, Mingru Zhang, Guiyu Li, Zifan Zhu, Jia Wang, Taoqi Ma, Junling Wang and 4 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wenhui Ma *Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.ORCID 0000-0003-0997-7339
Shu Yang *Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Jiajun Ye *Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Zhiyong QuanDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Mingru ZhangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Guiyu LiDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Zifan ZhuDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Jia WangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Taoqi MaDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Junling WangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Yu LiuBeijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
Zhibo LiuBeijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
Fei KangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. fmmukf@qq.com.ORCID 0000-0003-0267-7819
Jing WangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. 13909245902@163.com.

Funding

Key Industry Innovation Chain of Shaanxi S2024-YF-ZDCXL-ZDLSF-0064Medical Research Project of the Xi'an Innovation Capacity Support Plan 23YXYJ0169National Natural Science Foundation of China 82122033National Natural Science Foundation of China 82402323National Natural Science Foundation of China 92259304Xijing Hospital Medical Personnel Training Promotion Project XJZT24JC15Xijing Hospital Medical Personnel Training Promotion Project XJZT24LZ03Xijing Hospital Medical Staff Technology Enhancement Program 2024XJSM04Xijing Hospital Medical Staff Technology Enhancement Program 2024XJSY35
6 · The paper itself

Abstract

purposeFT-FAPI (FT, fast treatment) is a new FAP inhibitor with the potential to be used as a drug in boron neutron capture therapy (BNCT). The aim of this prospective study was to compare the diagnostic performance of

methodsThe study enrolled patients with histologically confirmed GI tumors diagnosed between March 2024 to April 2025 in Xijing Hospital. All the patients underwent paired

resultsA total of 19 patients with GI tumors (12 males and 7 females) with a median age of 61.3 years (range, 40-75 years) were finally enrolled in this study. A total of 186 lesions were identified.

conclusion

Indexed as

Gastrointestinal NeoplasmsOrganophosphorus CompoundsPositron Emission Tomography Computed TomographyAdultAgedFemaleGallium RadioisotopesHumansMaleMiddle AgedProspective StudiesQuinolines68Ga-FAPIGallium RadioisotopesOrganophosphorus CompoundsQuinolinesFibroblast activation proteinFT-FAPIGastrointestinal tumorsHead-to-head comparison

Identifiers

PMID40464804

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.